LP
CRVS icon

LMR Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

LMR Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-29,858
Closed -$94.9K – 1460
2025
Q1 		$94.9K Buy
+29,858
New +$141K ﹤0.01% 1145
2023
Q2 		– Sell
-30,000
Closed -$27.3K – 948
2023
Q1 		$27.3K Hold
30,000
– – ﹤0.01% 987
2022
Q4 		$25.5K Hold
30,000
– – ﹤0.01% 1072
2022
Q3 		$25K Hold
30,000
– – ﹤0.01% 1146
2022
Q2 		$30K Hold
30,000
– – ﹤0.01% 1205
2022
Q1 		$49K Hold
30,000
– – ﹤0.01% 1195
2021
Q4 		$72K Hold
30,000
– – ﹤0.01% 1121
2021
Q3 		$145K Buy
+30,000
New +$88.8K ﹤0.01% 947

Other funds holding CRVS

O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return